Latest News

Bilibili Announces Most Popular Scientific Topics of 2023 among China's Young Generations

* AIGC-related video views surpassed 9 billion on Bilibili * Science and educational content rank as 2nd most searched category on Bilibili, accounting for 41% of total viewing time SHANGHAI, Nov. 3, 2023 /PRNewswire/ -- Bilibili Inc. ("Bilibili" or the "Company"), an iconic brand and a leadi...

2023-11-03 14:34 4241

CCTV+: Enamored by Jiangxi--Wild and Fanciful Thoughts

BEIJING, Nov. 3, 2023 /PRNewswire/ -- The enchanting landscapes and distinctive cultural allure ofJiangxi have been a wellspring of inspiration for both native and visiting artists. Through Lou Weiwen's creative perspective, this short film traces the roots of Bada Shanren Memorial Hall and revea...

2023-11-03 14:27 13204

Rattan Launches the Quercus - Premium Long-Range Cargo Ebike for a Better Commute

RANCHO CUCAMONGA, Calif., Nov. 3, 2023 /PRNewswire/ -- Rattan, a renowned name in the fat tire electric bike industry, is proud to announce the launch of its latest innovation – theRattan Quercus, a cargo ebike with ext...

2023-11-03 13:42 1806

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao,Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, indust...

2023-11-03 12:10 1552

COSRX Launches Groundbreaking The AHA BHA PHA LHA 35 Peel for a 10-Minutes Glass Skin Transformation

LOS ANGELES, Nov. 2, 2023 /PRNewswire/ -- COSRX, the derm favourite skincare brand trusted by skin enthusiasts alike for its innovative and highly effective products, is excited to unveil its latest breakthrough: The AHA BHA PHA LHA 35 Peel. This distinctive pink chemical exfoliator, introduced t...

2023-11-03 11:13 2168

Berry AI Welcomes Eric Marchant as New Member of Leadership Team

LEWES, Del., Nov. 1, 2023 /PRNewswire/ -- Berry AI, a leading provider of AI camera solutions for the QSR industry, is delighted to announce the appointment ofEric Marchant as the newest member of its leadership team. This strategic addition comes as Berry AI experiences unprecedented growth in r...

2023-11-03 10:08 3248

Delivering Excellent Player Performances at the PUBG Global Championship - the Impressive Infinix GT 10Pro

SHANGHAI, Nov. 2, 2023 /PRNewswire/ -- It's official - the annual PUBG Mobile Global Championship will formally kick off onNovember 2nd and run to December 10 th! Furthermore, renowned trendy mobile phone brand, Infinix, has announced its sponsorship of the competition, providing its impressive GT...

2023-11-03 10:00 4370

BLUETTI Unveils AC2A and AC70 Portable Generators for Fall Adventures

LAS VEGAS, Nov. 2, 2023 /PRNewswire/ -- The crisp air and vibrant colors of fall beckonpeople to the great outdoors. But before heading out on the weekend camping trips or cozy cabin getaways,people need a reliable power source to keep their gadgets charged and comforts in check. And BLUETTI, a tr...

2023-11-03 10:00 1761

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaft...

2023-11-03 09:15 1732

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the ...

2023-11-03 09:10 1590

Revamp Sports and Leisure Pursuits with High-End Products at the 134th Canton Fair

GUANGZHOU, China, Nov. 2, 2023 /PRNewswire/ -- Amidst great anticipation, Phase 3 of the 134th Canton Fair onsite exhibition commenced on October 31st, attracting throngs of global buyers eager to explore the latest trends. Showcasing an impressive array of sports and leisure products, the event ...

2023-11-03 08:00 2056

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...

2023-11-03 05:15 1239

【OTER Organic Makes its Mark in the North American Market, Bringing Taiwan's Organic Delights to Consumers】

NEW TAIPEI CITY, Nov. 2, 2023 /PRNewswire/ -- Leading Taiwanese organic food brand,CHENG YUAN ORGANIC CO., LTD .'s OTER Organic, has announced its expansion into the North American organic food market. As the initial step in this...

2023-11-02 23:00 1558

A green and low-carbon path: Shandong's answer to modernization practice with Chinese characteristics

BEIJING, Nov. 2, 2023 /PRNewswire/ -- A news report from China.org.cn on the green and low-carbon practices ofShandong province in China:   Between the Shandong and Liaoning Peninsulas, the sea glitters against the backdrop of the sunset, and waves surge to the ocean breeze,...

2023-11-02 21:00 1574

Complete Genomics and Basepair™ Announce Technology Integration Partnership

SAN JOSE, Calif. and NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Complete Genomics and Basepair, Inc today announced a technology integration partnership to accelerate the analysis and interpretation of genomic data generated by Complete Genomics' DNBSEQTM sequencing platforms*. The partnership gives ...

2023-11-02 21:00 2352

South Korean Space Startup TelePIX Partners with Mexican Geo-Info Company Thrusters Unlimited for Latin America and Caribbean Market Expansion

SEOUL, South Korea, Nov. 2, 2023 /PRNewswire/ -- TelePIX, a leading South Korean space startup, announced the signing of a Memorandum of Understanding (MOU) with Thrusters Unlimited, a Mexican geo-information company. The MOU was signed onOctober 17th, solidifying the commitment of both companies...

2023-11-02 21:00 1962

EcoFlow Unveils Black Friday Offers on Best-in-Class Power

Top home safeguard and power solutions make for the perfect gifts this holiday season SEATTLE, Nov. 2, 2023 /PRNewswire/ -- EcoFlow, a leading portable power and eco-friendly energy solutions company, is ready for Black Friday and offering unbeatable prices on portable power stations, solar gene...

2023-11-02 21:00 1926

Introducing 'Never Have I Ever': Pioneering the First-Ever Art Licensed Press-On Nails

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Revolutionizing the world of beauty and art, 'Never Have I Ever ' proudly unveils its first-ever artist-licensed press-on nails from the vibrant streets of NYC. This game-changing brand marries the intricacies of artistry with f...

2023-11-02 20:00 2104

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironmentwith Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in...

2023-11-02 20:00 1715

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio * I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myelom...

2023-11-02 20:00 2051